958 patients scheduled for total hip arthroplasty were randomized to different groups for thromboprophylaxis. In patients <60 years of age (n=600), randomization was to either rivaroxaban, enoxaparin, or placebo. In patients 60 years of age or older (n=358), randomization was to either rivaroxaban or enoxaparin. The purpose of this study was to determine if there were any significant differences between groups in the incidence of major surgical wound complications. Results demonstrated no significant differences between groups, in either patients <60 or >60 years of age, in the rate of major surgical wound complications.